Compare Skyworks Solutions Inc (SWKS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs Twist Bioscience Corp — how do they compare? Skyworks Solutions Inc trades at $76.18 (market cap $11.52B), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Skyworks Solutions Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SWKS | TWST | |
|---|---|---|
Market Cap | $11.52B | $8.26B |
Sector | Technology | Health |
52-Week High | $83.40 | $153.10 |
52-Week Low | $52.50 | $24.16 |
Enterprise Value | $11.40B | $8.18B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $75.38, up 1.84% with bullish technical signals from moving averages. The stock shows strong earnings momentum with three consecutive quarterly beats but faces revenue contraction from $5.5B in 2022 to $4.1B in 2025. Analyst consensus remains positive with 58% buy ratings, though the current price exceeds the $66.44 consensus target. Recent institutional buying and conference participation indicate continued market interest despite ongoing revenue challenges.
The outlook remains cautiously optimistic with AI data center growth providing upside potential, but declining revenue and margin compression present headwinds. Key risks include ongoing fiduciary investigations and competitive pressures in the semiconductor sector. The stock's elevated P/E ratio of 39 requires sustained earnings growth to justify current valuation levels.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
